

JUL 0 7 2008 W

Substitute for form 1449/PTO				Complete if Known			
				Application Number	10/510,876		
INFORMATION DISCLOSURE				Filing Date	June 20, 2005		
S	STATEMENT BY APPLICANT			First Named Inventor	Christine Power		
				Art Unit	1647		
(Use as many sheets as necessary)				Examiner Name	R. M. Deberry		
Sheet	1	of	1	Attorney Docket Number	SLII-P01-001		

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		

FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	
Initials*	No.1	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages Or Relevant Figures Appear	

Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. 'Applicant's unique citation designation number (optional). \* See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. \* Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \* Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	r Cite No. 1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-iss number(s), publisher, city and/or country where published.		T <sup>2</sup>			
	C26	Auerbach, R., "Angiogenesis Assays: Problems and Pitfalls", Cancer and Metastasis Review, 19: pp 167-172, 2000.				
	C27	Berendsen, HJC, "A Glimpse of the Holy Grail", Science, 282: 642-643, 1998.				
	C28	Cancer Introduction from Merck manual accessed 6/26/07				
	C29	Clinical Aspectes of Cancer from Merck Manual Accessed 6/26/2007.				
	C30	Designing Custom Peptides from SIGMA accessed 12/16/2004.				
	C31	Gastrointestinal Stromal Tumors from Merck Manual Accessed 2/25/2008.				
	C32	Gura T., "Cancer Models: Systems for Identifying New Drugs Are Often Faulty", Science, 278(5340): 1041-1042, enclosed pp. 1-6, 1997.				
	C33	Jain, RK., "Barriers to Drug Delivery in Solid Tumors", Scientific American, pp. 58-65, 1994				
	C34	Rudinger, J. "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence", JA Parsons Ed., pp. 1-7, 1976.				
	C35	Stomach Cancer from Merck Manual Accessed 2/25/2008.				
	C36	Voet and Voet, "Biochemistry", Second Edition, John Wiley & Sons, Inc., pp. 235-241, 1995.				

Examiner	Date	
Signature	 Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&#</sup>x27;Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.